🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Type 2 Diabetes Mellitus–Related Mortality in the United States, 1999 ... sciencedirect.com/science/articl… Mushood Ahmed JACC Journals

HF Collaboratory Muthu Vaduganathan Mona Fiuzat Christopher O'Connor Megha Gupta JACC Journals stuart pocock Miltonpacker “risks of subsequent HFH and cardiovascular death are markedly elevated following a hospitalization” Time to rethink the initiation/titration of GDMT Simultaneous initiation + rapid uptitration provides the greatest protection when patients need it the most

Our new publication in JACC Journals! 📈 2M+ deaths from #T2DM in US (1999-2023) 🚨 Spike during COVID ❤️ 626K+ CVD-linked deaths 🔗 Full study: sciencedirect.com/science/articl… Jamal Rana, MD Steve Greene Marat Fudim, MD MHS Robert Mentz, MD Gregg Fonarow MD

Published! 🚨 Check out our recent publication in JACC Journals! Read the full study: doi.org/10.1016/j.jaca…

🔥 #VICTORIA substudy: #ICD in ischaemic vs non-ischaemic #heartfailure: ✅ Significant ⬇️ od #SCD ❌ No significant ⬇️ of CV ☠️ A long question with still many trials ongoing 🍀 EJHF Editor-in-Chief Andrew J Sauer MD BiykemBozkurt Johann Bauersachs Gregg Fonarow MD Steve Greene bit.ly/4jZCuz5

Patience you must have. The SURMOUNT MMO trial design #obesity #Tirzepatide onlinelibrary.wiley.com/doi/10.1002/ob…

1970-2022 89% ⬇️ in age‐adjusted ☠️ from AMI and an 81% ⬇️ in age‐adjusted ☠️ from all ischemic heart disease. 81% ⬆️ in age‐adjusted ☠️ from heart failure, hypertensive heart disease, and arrhythmia ahajournals.org/doi/10.1161/JA…

Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead IMPROVING QUALITY OF CARE AND INTEGRATING NOVEL THERAPIES APPLYING CLINICAL TRIAL FINDINGS TO REAL-WORLD PROMOTING QUALITY IMPROVEMENT AND INNOVATION ahajournals.org/doi/10.1161/CI…

Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF Although an initial decline in eGFR was associated with worse outcomes in patients assigned to placebo, this relationship was not as strong in those treated with

So excited to welcome this year’s newest class of cardiology fellows! We’re so thrilled to have you here and can’t wait for all that you’ll bring to the Duke Heart family!🫀🔥 Duke Cardiology Duke Clinical Research Institute

Exploring safety of down-titrating #diuretics in heart failure management : Post-hoc analysis of #TIME-CHF (n=622): Avg age: 77y | 59% male | 76% #NYHA III/IV 30-day outcomes after loop diuretic down-titration: 🔺30.4% needed re-up 🏥 Hospitalization: 3.4% ⚰️ Death: 2.0%

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry Guidelines recommend treating most patients with heart failure with RAASi. Hyperkalemia may hinder achieving

🔥 Residual #PulmonaryHypertension & Clinical outcome in #AHF across #LVEF 🚨 Presence of #PH predicts #All_cause ☠️ & #HHF 🏥 irrespective of #LVEF No difference #HFrEF #HFmrEF #HFpEF #HFUA 🫀🍀 European Society of Cardiology Journals EJHF Editor-in-Chief Michele Emdin Andrew J Sauer MD bit.ly/44ioOLd

HOTLINES ESC 2025 Madrid HOT LINE 1 29 August from 11:00 to 12:00 Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study The DIGIT-HF trial will provide

ESC Congress Madrid 2025 HOT LINE 2 30 August from 08:15 to 09:45 Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial VICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational

Substantial opportunity to improve HF care in US cardiology outpatient practices Findings from the American College of Cardiology NCDR PINNACLE registry jamanetwork.com/journals/jamac… Larry A. Allen, MD Steve Greene JAMA Cardiology

Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care Although this study found that SGLT2i use had increased among ambulatory patients with HF during the study period, the majority of eligible patients did not receive this therapy.

In a nationwide study of outpatients with heart failure, a majority eligible for SGLT2i therapy did not receive it, particularly those who were older, female, or with higher blood pressure. ja.ma/4eLrYuA @GCFMD

Study Highlights Rate of Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure hcplive.com/view/study-hig… via @hcplive JAMA Cardiology